Market News (Page 88) - TendieTensor

Market News Page 88 of 161 • 4,014 articles

Bath & Body Works Declares Cash Dividend

Benzinga • Globe Newswire

Bath & Body Works Declares Cash Dividend

11/07/2025 08:30 AM • Bath & Body Works announced a quarterly cash dividend of $0.20 per share, payable on December 5, 2025, to shareholders of record as of November 21, 2025.

UBER - Mentioned as a recent partnership with Lucid, but no specific sentiment analysis provided
BBWI - Company is maintaining consistent dividend payments, indicating financial stability and commitment to shareholder value

#dividend #quarterly #cash dividend #shareholders

BlackSky CEO Brian O'Toole Named 'Executive of the Year' at the 2025 Greater Washington GovCon Awards

Benzinga • Business Wire

BlackSky CEO Brian O'Toole Named 'Executive of the Year' at the 2025 Greater Washington GovCon Awards

11/07/2025 08:30 AM • BlackSky Technology CEO Brian O'Toole was honored as 'Executive of the Year' in the $75 to $300 million annual revenue category, recognizing his leadership in space-based intelligence and contributions to the government contracting industry.

TSLA - Mentioned as a competitive benchmark in the EV market
BKSY - The article highlights the company's achievements, industry leadership, and CEO's recognition, indicating strong performance and positive organizational momentum

#Earth observation #geospatial intelligence #satellite #government contracts #space technology

Warren Buffett's Warning to Wall Street has Reached Deafening Levels: 3 Things You Should Do Before 2026.

The Motley Fool • James Brumley

Warren Buffett's Warning to Wall Street has Reached Deafening Levels: 3 Things You Should Do Before 2026.

11/07/2025 08:15 AM • Warren Buffett is cautious about current stock market valuations, holding $381.6 billion in cash and suggesting investors prepare for a potential market correction by maintaining liquidity, identifying high-quality long-term stocks, and monitoring market trends.

XRT - Trailing S&P 500 performance and experiencing economic uncertainties in the retail sector
BRK.A - Holding significant cash reserves indicates caution about current market conditions, but not completely abandoning stock investments

#Warren Buffett #market valuation #cash reserves #investment strategy #stock market correction

IES Holdings to Acquire Gulf Island Fabrication

Benzinga • Globe Newswire

IES Holdings to Acquire Gulf Island Fabrication

11/07/2025 08:15 AM • IES Holdings will acquire Gulf Island Fabrication for $12.00 per share, representing a 52% premium, in a strategic move to expand infrastructure and data center service capabilities.

IESC - Expanding service capabilities, strategic acquisition at a premium, complementary business with potential for growth in infrastructure and data center markets

#acquisition #steel fabrication #infrastructure #data centers #merger

Legacy Housing Announces Agreement to Purchase Assets of AmeriCasa Solutions, LLC and Addition of New Senior Management

Benzinga • Globe Newswire

Legacy Housing Announces Agreement to Purchase Assets of AmeriCasa Solutions, LLC and Addition of New Senior Management

11/07/2025 08:14 AM • Legacy Housing Corporation has agreed to purchase the assets of AmeriCasa Solutions, including its FutureHomeX® Platform, in an all-cash transaction. Norman Newton, AmeriCasa's CEO, will join Legacy Housing as Chief Revenue Officer to help accelerate sales growth and technology integration.

LEGH - Expanding business through strategic acquisition, adding new technology platform, and bringing experienced leadership to drive growth

#manufactured homes #acquisition #technology platform #sales growth #strategic partnership

S&P 500: Price Weakness Signals Potential Trend Change

Investing.com • Peter B. Levant

S&P 500: Price Weakness Signals Potential Trend Change

11/07/2025 08:13 AM • The S&P 500 is showing technical weakness, closing below multiple moving averages and potentially signaling a short-term trend reversal. The critical 50-day moving average is being tested, which could trigger systematic selling if breached.

BRKRP - Actively expanding capabilities through strategic investments and acquisitions, such as acquiring Bridge12's Electron Paramagnetic Resonance business and investing in RECIPE Chemicals + Instruments
AAPL - Mentioned in market movers list with minimal price movement (-0.14%)

#S&P 500 #market trend #technical analysis #moving averages #market correction

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

GlobeNewswire Inc. • Sanofi And Regeneron

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

11/07/2025 08:00 AM • Sanofi and Regeneron's Dupixent demonstrated significant improvements in treating allergic fungal rhinosinusitis (AFRS) in a phase 3 study, with the FDA accepting the supplemental biologics license application for priority review.

SNY - Positive clinical trial results, FDA priority review acceptance, potential new treatment indication expanding Dupixent's market

#Dupixent #AFRS #clinical trial #FDA #phase 3 study

Karbon-X Expands Blue Carbon Leadership with New Restoration Project in Guinea

GlobeNewswire Inc. • Alexis Leroy

Karbon-X Expands Blue Carbon Leadership with New Restoration Project in Guinea

11/07/2025 08:00 AM • Karbon-X is expanding its mangrove restoration efforts from Senegal to the Konkouré Delta in Guinea, focusing on coastal restoration, biodiversity protection, and community resilience through blue carbon projects.

KARX - Company is demonstrating proactive environmental leadership by scaling successful mangrove restoration projects, generating carbon reductions, and creating community benefits across West Africa

#mangrove #blue carbon #coastal restoration #climate investment #sustainability

Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025

GlobeNewswire Inc. • Judy Matthews

Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025

11/07/2025 08:00 AM • Iterum Therapeutics will release its third quarter 2025 financial results on November 14, 2025, with a conference call to discuss results and provide a business update. The company has received FDA approval for ORLYNVAH, an oral antibiotic for treating urinary tract infections.

DE - Mentioned as part of newly elected Board of Directors without specific context
ITRM - Company received FDA approval for ORLYNVAH, has Fast Track and QIDP designations, and is hosting a financial results conference call, indicating ongoing business development and progress

#antibiotics #financial results #FDA approval #multi-drug resistant pathogens

Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting

GlobeNewswire Inc. • Immunocore Holdings Plc

Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting

11/07/2025 08:00 AM • Immunocore announced Phase 1 trial results for IMC-I109V, a T cell receptor bispecific candidate targeting hepatitis B virus, showing promising dose-dependent HBsAg reduction and a generally manageable safety profile.

IMCR - Positive trial results demonstrating potential efficacy and safety of IMC-I109V, with dose-dependent HBsAg reduction and manageable adverse events

#hepatitis B #immunotherapy #clinical trial #T cell receptor #bispecific #antiviral

Dycom Industries, Inc. to Host Fiscal 2026 Third Quarter Results Conference Call

GlobeNewswire Inc. • Callie Tomasso

Dycom Industries, Inc. to Host Fiscal 2026 Third Quarter Results Conference Call

11/07/2025 08:00 AM • Dycom Industries will host a fiscal 2026 third quarter results conference call on November 19, 2025, at 9:00 a.m. ET, with options for live audio webcast and replay.

DY - Standard quarterly earnings conference call announcement with no explicit positive or negative financial indicators

#conference call #earnings #investor relations #telecommunications

Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique...

GlobeNewswire Inc. • Sanofi And Regeneron

Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique...

11/07/2025 08:00 AM • A phase 3 clinical study of Dupixent demonstrated significant improvements in treating allergic fungal rhinosinusitis (AFRS), reducing sinus opacification, nasal congestion, and nasal polyps. The FDA has accepted the supplemental Biologics License Application with priority review.

SNY - Positive clinical trial results with potential new FDA-approved indication for Dupixent, expanding the drug's market potential

#Dupixent #AFRS #clinical trial #FDA #rhinosinusitis

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

GlobeNewswire Inc. • Atea Pharmaceuticals

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

11/07/2025 08:00 AM • Atea Pharmaceuticals presented modeling data showing their combination drug regimen of bemnifosbuvir and ruzasvir could potentially provide a short-duration, highly effective treatment for hepatitis C virus, with near-complete viral inhibition and a modeled cure time of 7-8 weeks.

AVIR - Company presented promising research data demonstrating high efficacy of their drug combination, with potential to transform HCV treatment landscape, achieve high sustained virologic response rates, and address patient needs

#hepatitis C virus #antiviral therapeutics #bemnifosbuvir #ruzasvir #clinical trials

AirJoule Technologies Schedules Release of Third Quarter 2025 Results and Conference Call

GlobeNewswire Inc. • Tom Divine

AirJoule Technologies Schedules Release of Third Quarter 2025 Results and Conference Call

11/07/2025 08:00 AM • AirJoule Technologies will report its third quarter 2025 financial results on November 13, 2025, with a conference call and Q&A session scheduled for November 14, 2025 at 8:30 AM ET.

A - Engaged in collaborative efforts to enhance biomolecular analysis technologies by partnering with Isospec Analytics
AIRJ - Standard financial reporting announcement with no explicit positive or negative indicators

#financial results #conference call #quarterly earnings #investor relations

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Benzinga • Prnewswire

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

11/07/2025 07:30 AM • Soligenix reported a net loss of $2.5 million in Q3 2025, with ongoing clinical trials for HyBryte™ in cutaneous T-cell lymphoma and continued development of rare disease treatments. The company maintains approximately $10.5 million in cash and is focused on strategic milestones through 2026.

GOOG - Primarily driven by Google Search revenue, introduced AI Search Overviews, survived potential monopoly breakup, and has stable core business
SNGX - The company reported a financial loss but is progressing with clinical trials, maintaining a strategic focus on product development and potential commercialization. The neutral sentiment reflects ongoing development without significant positive or negative breakthroughs.

#biopharmaceutical #rare diseases #clinical trials #HyBryte #CTCL #financial results

1 Growth Stock Down 52% to Buy Hand Over Fist Heading Into 2026

The Motley Fool • Lee Samaha

1 Growth Stock Down 52% to Buy Hand Over Fist Heading Into 2026

11/07/2025 07:30 AM • Aehr Test Systems, a semiconductor testing company focused on electric vehicle and AI processor markets, is positioned for potential growth despite recent sales decline, with analysts expecting stabilization and future revenue expansion.

AEHR - Despite a 52% stock price drop and mid-teens sales decline, the company shows promise in EV and AI processor testing markets, with potential growth from hyperscaler orders and expected market recovery

#semiconductor #electric vehicles #AI processors #technology #testing systems

TOUCHMARK BANCSHARES, INC. REPORTS THIRD QUARTER RESULTS

Benzinga • Prnewswire

TOUCHMARK BANCSHARES, INC. REPORTS THIRD QUARTER RESULTS

11/07/2025 07:26 AM • Touchmark Bancshares reported a 65% increase in net income to $609,000 in Q3 2025, with improved net interest margin and strategic deposit management. The bank expects positive loan growth in Q4 2025 and reduced non-performing assets.

GOOGL - Primarily driven by Google Search revenue, introduced AI Search Overviews, survived potential monopoly breakup, and has stable core business
TMAK - Increased net income by 65%, reduced non-performing assets, strategic deposit management, and positive loan growth outlook indicate strong financial performance and management strategy

#banking #financial results #loan growth #net income #deposit management

Why D.R. Horton Stock Fell 12% in October

The Motley Fool • Jeremy Bowman

Why D.R. Horton Stock Fell 12% in October

11/07/2025 07:21 AM • D.R. Horton experienced a 12% stock decline in October due to weak housing market conditions, an analyst downgrade, and underwhelming fourth-quarter earnings that showed falling revenue and profits.

META - Primarily ad-revenue based, seeing improvements with AI implementation, can pause AI investments without significant business disruption
DHI - Company reported falling revenue (-3.3%), decreased earnings per share from $3.92 to $3.04, received analyst downgrades, and provided flat revenue guidance for 2026

#homebuilder #housing market #mortgage rates #earnings #stock decline

The Motley Fool • Anders Bylund

Where Will Netflix Be in 5 Years?

11/07/2025 07:19 AM • Netflix is expanding beyond streaming by diversifying into ads, gaming, real-world experiences, music, and podcasts, aiming to create a multi-dimensional media ecosystem similar to Disney's strategy.

NFLX - The article suggests Netflix is strategically evolving by adding multiple revenue streams, exploring new business models, and maintaining innovative growth potential

#streaming #diversification #media #innovation #expansion

3 Dirt Cheap Stocks to Buy With $1,000 Right Now

The Motley Fool • James Brumley

3 Dirt Cheap Stocks to Buy With $1,000 Right Now

11/07/2025 07:15 AM • The article highlights three undervalued stocks: Merck, Verizon, and Goldman Sachs, which offer potential investment opportunities amid an AI-driven market rally. Each company presents unique strengths in their respective industries, with attractive valuations and potential for future growth.

NMHI - Acquired global rights to advanced carbon credit tokenization technology, enhancing environmental technology platforms and expanding market opportunities in Asia
MRK - Strong drug development pipeline with 20 potential drugs, preparing for Keytruda patent expiration, attractive dividend yield of 3.8%, and low valuation at 9x next year's earnings

#stocks #investment #undervalued #pharmaceutical #telecommunications #finance

Why Is Pinterest Stock Crashing, and Is It a Buying Opportunity?

The Motley Fool • Parkev Tatevosian, Cfa

Why Is Pinterest Stock Crashing, and Is It a Buying Opportunity?

11/07/2025 07:15 AM • Pinterest reported quarterly financial results that disappointed investors, with stock price falling due to tariff impacts on retail advertisers, despite adding monthly active users in its most lucrative region.

PINS - Stock price dropped after quarterly earnings report, with disappointing financial results and potential challenges from tariffs affecting retail advertisers

#Pinterest #stock #earnings #tariffs #retail advertising

Prediction: Alphabet Stock Will Soar 50% by 2026

The Motley Fool • Rick Orford

Prediction: Alphabet Stock Will Soar 50% by 2026

11/07/2025 07:15 AM • Alphabet reported record-breaking earnings, surpassing $100 billion in revenue and accelerating its AI-driven transformation. With Gemini scaling globally and Google Cloud hitting new highs, analysts predict significant stock growth by 2026.

DJTWW - Stock jumped 6% premarket, announced innovative platform expansion, reported $3 billion in cash reserves, and achieved first quarter of positive operating cash flow
GOOG - Strong quarterly earnings, global AI expansion, record revenue, and potential for 50% stock price increase by 2026

#Alphabet #AI #earnings #Google Cloud #Gemini

DigitalOcean’s Tide Has Turned: Get Ready to Ride the Wave

Investing.com • Thomas Hughes

DigitalOcean’s Tide Has Turned: Get Ready to Ride the Wave

11/07/2025 07:08 AM • DigitalOcean reported strong Q3 results with 16% revenue growth, driven by AI and cloud services. The company showed significant improvements in financial metrics and received positive analyst responses, suggesting potential for future growth.

DOCN - Q3 revenue exceeded guidance, 41% increase in large clients, 138% net income improvement, strong AI-driven demand, and positive analyst upgrades

#AI #cloud services #infrastructure #earnings #technology

Elon Musk's $1 Trillion Pay Package Gets Green Light — Critics Call It 'Oligarchy,' Supporters Hail 'Decisive Statement'

Benzinga • Badar Shaikh

Elon Musk's $1 Trillion Pay Package Gets Green Light — Critics Call It 'Oligarchy,' Supporters Hail 'Decisive Statement'

11/07/2025 07:01 AM • Tesla shareholders approved Elon Musk's $1 trillion pay package with 75% voting in favor, despite criticism from proxy advisors and some public figures like Bernie Sanders who called it an 'oligarchy'.

AMJB - Highlighted as an example of a reliable, long-term investment stock
TSLA - Shareholders overwhelmingly approved the pay package, with supporters like Michael Dell and Dan Ives praising Musk's leadership and long-term vision

#Tesla #Elon Musk #compensation #shareholders #pay package

Complete Tumor Regressions Observed in Preclinical Models with Co-administration of Cyncado’s A2B and A2A Receptor Antagonists and Cancer Vaccines

GlobeNewswire Inc. • Alphaton Capital Corp

Complete Tumor Regressions Observed in Preclinical Models with Co-administration of Cyncado’s A2B and A2A Receptor Antagonists and Cancer Vaccines

11/07/2025 07:00 AM • Researchers at the National Cancer Institute demonstrated complete tumor regressions using co-administered A2B and A2A receptor antagonists with cancer vaccines across multiple cancer models, showing promising preclinical results for potential cancer immunotherapy.

VYLD - Highlighted as an example of a reliable, long-term investment stock
ATON - Advancing promising oncology research through subsidiary, with clear strategic goals in developing innovative cancer therapies

#immunotherapy #cancer vaccines #tumor regression #adenosine receptor antagonists